## **Pharmaceutical Fronts**

## **Author Instructions**

Thank you for contributing to *Pharmaceutical Fronts*. Please read the instructions carefully and observe all the directions given.

Failure to do so may result in unnecessary delays in publishing your article.

All article processing charges (APCs) are fully sponsored by the China National Pharmaceutical Industry Information Center. Upon acceptance, no APC is due by the author. For current prices, please visit Open Access - Journal authors - Thieme Group, navigate to "APC", and select the Price List. APCs are regularly reviewed and may be subject to change. No additional fees, including submission fees, editorial processing charges, or page and color charges apply.

SUBMISSION CHECKLIST						
Papers would be processed via Online Platform: https://www.editorialmanager.com/pf						
	AUTHOR INFORMATION  - All authors: full name, department, affiliation  - Corresponding author: full name, degrees, department, affiliation, mailing address, telephone and fax number, e-mail address					
	MANUSCRIPT FILE - Must be digital - hard copy submissions are not accepted					
	ABSTRACT AND KEYWORDS - See the section Article Types for word limit					
	REFERENCES - Cited sequentially in AMA style					
	FIGURES AND TABLES  - Cited sequentially in the main document, must be saved separately from the main document					
	ART FILES  - Must be saved separately from the main document					
	PERMISSIONS  - Required if you plan to reproduce content from a published source or include a photograph of a patient  - Patient permission forms available at <a href="https://www.thieme.com/journal-authors">www.thieme.com/journal-authors</a>					

CONTENTS	
MANUSCRIPT FORMAT	3-7
Article Types	3
General Guidelines	3
Title Page	4
Abstract and Keywords	4
Main Document	4
Acknowledgments	5
Conflict of Interest	5
Informed Consent	5
References	6
Figure Captions	7
Tables	7
Videos	7
DIGITAL ARTWORK PREPARATION	8
General Guidelines	8
Black and White Art	8
Color Art	8
Art Labels	8
SUBMISSION PROCEDURE	9
Article Processing Charge (APC)	9
Submission Procedure	9
Revision Procedure	9
Peer Review Policy	9
PRODUCTION PROCEDURE	10
Page Proofs	10
POLICY STATEMENTS	10-11
Statement on Liability	10
Definition of Authorship	10
Copyright Statement	10
Clinical Trials	10
Ethics	10
Patient Permission Policy	11
EDITORIAL CONTACTS	12

## **MANUSCRIPT FORMAT**

## **Article Types**

The following graph shows what types of articles are accepted for publication, and what requirement they may have.

Article Type	Abstract Limit	Keywords Limit	Title Limit
Original Article	300 words	3 to 5 key words	No Limit
Review	300 words	3 to 5 key words	No Limit
Short Communication	120 words	3 key words	No Limit
Commentary	_	-	-

#### **General Guidelines**

- You must submit a digital copy of your manuscript. Hard copy submissions are not accepted.
- Keep the format of your manuscript simple and clear. We will set your manuscript according to our style—do not try
  to "design" the document.
- The manuscript, including the title page, abstract and keywords, text, references, figure captions, and tables should be typewritten, double-spaced in 12-point font with 1-inch margins all around and saved as one file.
- Indicate the type of manuscript in the title, choosing from Original article, Review, Short Communication and commentary.
- Commentary should be a maximum of 1500 words and have a maximum of ten references.
- Title page, Abstract, Main Text, Figure Legend, and References should be saved on a separate file.
- Each figure should be saved as its own separate file. Do not embed figures within the manuscript file. This requires special handling by Thieme's Production Department.
- Keep abbreviations to a minimum and be sure to explain all of them the first time they are used in the text.
- The manuscripts should be written in consistent British or American English.
- The authors should use Système International (SI) measurements. For clarity, nonmetric equivalents may be included in parentheses following the SI measurements.
- Use generic names for drugs. You may cite proprietary names in parentheses along with the name and location of the manufacturer.
- Credit suppliers and manufacturers of equipment, drugs, and other brand-name material mentioned in the manuscript within parentheses, giving the company name and primary location.

## **MANUSCRIPT FORMAT continued**

## **Title Page**

- This journal adheres to a double-blinded peer-review policy. The title page should NOT be included in the main document.
- The title page should list the article title and the corresponding author's full name, degree, title, department, affiliation, mailing address, e-mail address, and telephone and fax numbers. It should also list the full name, department, and affiliation of every co-author.
- Authors are required to disclose all financial and personal relationships that might influence their work, and all
  authors should disclose possible conflicts of interest, in their title page.

#### **Abstract and Keywords**

- The abstract should be prepared on a separate page, and must not exceed 300 words in length. (As for Short communication must not exceed 120 words in length)
- 3-5 keywords should be supplied. (As for Short communications, 3 key words should be supplied).
- The purpose of the investigation should be stated, followed by a description of the study design or experimental procedure, main findings or major contributions, and finally the specific conclusion or recommendations.
- Sufficient information should be included for the abstract to be easily understood without reference to the text, and
  any new and important aspects of the study should be emphasized.

## **Main Document**

- Text is to be divided into sections with the following headings consecutively in principle: Introduction, Material and Methods, Results, Discussion, Conclusion and Acknowledgement (if needed).
- Papers including human or animal subjects must include a statement of approval by appropriate agencies in the text.
- Use generic names of drugs or devices. If a particular brand was used in a study, insert the brand name along with the
  name and location of the manufacturer in parentheses after the generic name when the drug or device is first
  mentioned in the text.
- Quantities and units should be expressed in accordance with the recommendations of the International System of Units (SI), 8th edition 2006 (www.bipm.orgutilscommonpdfsi\_brochure\_8\_en.pdf).
- When abbreviations are used, give the full term followed by the abbreviation in parentheses the first time it is mentioned in the text, such as inferior gleno-humeral ligament (IGHL).
- Please clearly distinguish the hierarchy of headings within the manuscript by using capital letters, underline, italic, and bold styles as necessary.
- As needed, use italic, superscripts, subscripts, and boldface, but otherwise do not use multiple fonts and font sizes.
- Do not insert page or section breaks except where noted in the Author Instructions.
- Use hard returns (the Enter key) only at the end of a paragraph, not at the end of a line. Allow lines of text to break automatically in your word-processing software. Do not justify your text.
- Use only one space, not two, after periods.
- Create tables using the Table function in Microsoft Word.

## **Thieme Editing Services**

Thieme offers a language editing service for manuscripts, abstracts and theses in partnership with Enago, a world-leading provider of author services to researchers around the world. Authors can choose from a range of editing services and get their manuscripts edited by Enago's professional medical editors. Authors that wish to use this service will receive a 20% discount on all editing services. To find out more information or get a quote, please visit <a href="https://www.enago.com/thieme">https://www.enago.com/thieme</a>

## Acknowledgments

The source of any financial support received and recognition of personal assistance for the work being published should be indicated at the end of the article, just before the Reference section, under the heading Acknowledgments.

## **Conflict of Interest**

All authors (including corresponding and co-authors associated with the manuscript) must make a formal statement at the time of submission indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. Should the article be accepted for publication, this information will be published with the paper.

Types of conflicts include: Consulting, Royalties, Research Support, Institutional Support, Ownership, Stock/Options, Speakers Bureau, and Fellowship Support. Any commercial entity whose products are described, reviewed, evaluated, or compared in the manuscript, except for those disclosed in the Acknowledgments section, are potential conflicts.

This journal follows the guidelines of the <u>International Committee of Medical Journal Editors</u> and an <u>ICMJE disclosure of potential conflicts of interest (COI) form</u> must be submitted for each author at the time of manuscript submission. Forms must be submitted even if there is no conflict of interest. It is the responsibility of the corresponding author to ensure that all authors adhere to this policy prior to submission.

A conflict of interest statement must also be included in the manuscript after any "Acknowledgements" and "Funding" sections and should summarize all aspects of any conflicts of interest included on the ICMJE form. If there is no conflict of interest, authors must include 'Conflict of Interest: none declared'.

Please click <a href="http://www.icmje.org/conflicts-of-interest">http://www.icmje.org/conflicts-of-interest</a> to download a Conflict of Interest form. The disclosure information is important in article processing. If the provided forms are incomplete or missing, it can cause delays in publishing of article.

## **Informed Consent**

The journal adheres to the principles set forth in the <u>Helsinki Declaration</u> and holds that all reported research conducted with human participants should be conducted in accordance with such principles. Reports describing data obtained from research conducted in human participants must contain a statement in the Methods section indicating approval by the Institutional Review Board (IRB). The authors should also indicate whether or not individual consent for the study was obtained, or whether it was waived.

## **MANUSCRIPT FORMAT continued**

#### References

References should be the most recent and pertinent literature available. It is essential that they are complete and thoroughly checked. If the reference information is incomplete, good online sites to search for full details are the National Library of Medicine: <a href="www.nlm.nih.gov">www.nlm.nih.gov</a>; Books in Print: <a href="www.booksinprint.com">www.booksinprint.com</a>; PubMed: <a href="www.ncbi.nlm.nih.gov/PubMed/">www.ncbi.nlm.nih.gov/PubMed/</a>; or individual publisher Web sites.

- References must be listed in AMA style, using Index Medicus journal title abbreviations.
- References follow the article text. Insert a page break between the end of text and the start of references.
- References must be cited sequentially (NOT alphabetically) in the text using superscript numbers.
- By way of exception to AMA style, do not italicize book titles or journal title abbreviations and do not put a period at the end of a reference.
- List all author names, up to and including six names. For more than six authors, list the first three followed by et al.
- References should be styled per the following examples:

#### 1. Citing a journal article:

Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma-globulin. N Engl J Med 1986;315:341–347

#### 2. Citing a chapter in a book:

Toma H. Takayasu's arteritis. In: Novick A, Scoble J, Hamilton G, eds. Renal Vascular Disease. Philadelphia: WB Saunders; 1995:47–62

#### Citing a book:

Stryer L. Biochemistry. 2nd ed. San Francisco: WH Freeman; 1981:559–596

#### 4. Citing a thesis:

Stern I. Hemorrhagic Complications of Anticoagulant Therapy [Ph.D. dissertation]. Evanston, IL: Northwestern University; 1994

## 5. Citing a government publication:

Food and Drug Administration. Jin Bu Huan Herbal Tablets. Rockville, MD: National Press Office; April 15, 1994. Talk Paper T94-22

## 6. Citing an online article:

Rosenthal S, Chen R, Hadler S. The safety of acelluler pertussis vaccine vs whole-cell pertussis vaccine [abstract]. Arch Pediatr Adolesc Med [serial online]. 1996;150:457–460. Available at: http://www.ama-assn.org/sci-pubs/journals/archive/ajdc/vol\_150/no\_5/abstract/htm. Accessed November 10, 1996

## 7. Citing a symposium article:

Eisenberg J. Market forces and physician workforce reform: why they may not work. Paper presented at: Annual Meeting of the Association of American Medical Colleges; October 28, 1995; Washington, DC

#### **MANUSCRIPT FORMAT continued**

## **Figure Captions**

- Figures include photographs, drawings, graphs, bar charts, flow charts, and pathways, but NOT lists or tables.
- Figure prepared by the author(s) will be used in the online version of the journal. Cite each figure in the text and mark in the right margin of the page.
- Figures must be cited sequentially in the text. Number all figures (and corresponding figure captions) sequentially in the order they are cited in the text.
- Figure captions should be written after the reference list. Insert a page break between the end of references and the start
  of figure captions.
- Figure captions should include a description of the figure and/or each lettered part (A, B, etc.) and of any portions of the figure highlighted by arrows, arrowheads, asterisks, etc.
- For a figure borrowed or adapted from another publication (used with permission), add a credit line in parentheses at the end of each figure legend. This credit line should be a complete bibliographic listing of the source publication (as a reference), or other credit line as supplied by the copyright holder. For example (Reprinted with permission from Calfee DR, Wispelwey B. Brain abscess. Semin Neurol 2000;20:357.)
- If a figure has already been published, it is the author's responsibility to obtain written permission to reproduce or modify from the copyright holder, and acknowledge the original source in the legend
- Short Communication should be composed of 2 sheets or less of figures.

#### **Tables**

- Data given in tables should be commented on but not repeated in the text. Be sure that lists or columns of related data are composed in a word-processing program like the rest of the text.
- Do not intersperse tables in the text. Tables should appear after the figure captions. Insert a page break between the end of the figure captions and the start of the tables.
- Tables must be double-spaced and numbered in the same sequence they are cited in the text. A short descriptive title should be provided for each table.
- If a table contains artwork, supply the artwork separately as a digital file.
- For tables borrowed or adapted from another publication (used with permission), add a credit line as the first footnote beneath each table. This credit line should be a complete bibliographical listing of the source publication (as a reference), or other credit line as supplied by the copyright holder. For example, "Reprinted with permission from Calfee DR, Wispelwey B. Brain abscess. Semin Neurol 2000;20:357." ("Data from . . ." or "Adapted from . . ." may also be used, as appropriate.)
- Other footnotes for tables should be indicated in the table using superscript letters in alphabetical order.
- Any abbreviations used in the table should be explained at the end of the table in a footnote.

#### **Videos**

- The following formats are acceptable: \*.avi, \*.mov and \*.mpg.
- For supplementary videos, the length should not exceed 4 minutes, and a legend of no more than 40 words per video or per sequence is required (it should also be included in the main document).
- If including a voice over, it must be in clear English. Be precise, informative, and clear in your speech. Re-record audio in post-production for sound quality.

#### **DIGITAL ARTWORK PREPARATION**

#### **General Guidelines**

- It is best to use Adobe Photoshop to create and save images, and Adobe Illustrator for line art and labels.
- Do not submit art created in Microsoft Excel, Word, or PowerPoint. These files cannot be used by the typesetter.
- Save each figure in a separate file.
- Do not compress files.
- All black-and-white and color artwork should be at a resolution of 300 dpi (dots per inch) in TIFF format. Line art should be 1,200 dpi in EPS or TIFF format. Contact the Production Editor at Thieme if you are unsure of the final size.
- It is preferable for figures to be cropped to their final size (approximately 3½ inches for a single column and up to 7 inches for a double column), or larger, and in the correct orientation. If art is submitted smaller and then has to be enlarged, its resolution (dpi) and clarity will decrease.

**Note**: Lower resolutions (less than 300 dpi) and JPEG format (.jpg extension) for grayscale and color artwork are strongly discouraged due to the poor quality they yield in printing, which requires 300 dpi resolution for sharp, clear, detailed images. JPEG format, by definition, is a lower resolution (compressed) format designed for quick upload on computer screens.

#### **Black-and-White Art**

- Black-and-white artwork can be halftone (or grayscale) photographs, radiographs, drawings, line art, graphs, and flowcharts. Thieme will only accept digital artwork.
- If possible, do not send color art for conversion to black-and-white. Do the conversion yourself so that you can check the results and confirm in advance that no critical details are lost or obscured by the change to black-and-white.
- For best results, line art should be black on a white background. Lines and type should be clean and evenly dark. Avoid screens or cross-hatching, as they can darken or be uneven in printing and lead to unacceptable printing quality.

## **Color Art**

All color artwork should be saved in CMYK, not RGB.

#### **Art Labels**

- Arrows, asterisks, and arrowheads (or other markers) should be white in dark or black areas and black in light or white
  areas, and large in size. If not, these highlighting marks may become difficult to see when figures are reduced in size during
  the typesetting process.
- Use 1-point (or thicker) rules and leader lines.
- Capitalize the first word of each label and all proper nouns. Consider using all capitals if you need a higher level of labels.
- Where there are alternate terms or spellings for a named structure, use the most common one and make sure it is consistent with what is used in the text.
- Avoid using multiple fonts and font sizes for the labels; use only one or two sizes of a serif font.

#### SUBMISSION PROCEDURE

## **Article Processing Charge (APC)**

All article processing charges (APCs) are fully sponsored by the China National Pharmaceutical Industry Information Center. Upon acceptance, no APC is due by the author. For current prices, please visit Open Access - Journal authors - Thieme Group, navigate to "APC", and select the Price List. APCs are regularly reviewed and may be subject to change. No additional fees, including submission fees, editorial processing charges, or page and color charges apply.

## **Submission Procedure**

- Consult the checklist on the first page of this document to ensure that you are ready to submit your manuscript.
- Please note: There are no submission charges to submit your manuscript to this journal.

#### **Preprint Server Statement**

Pharmaceutical Fronts encourages the submission of manuscripts that have been deposited in an initial draft version in preprint repositories such as Research Square, arXiv, and medRxiv. Drafts of short conference abstracts or degree theses posted on the website of the degree-granting institution, and draft manuscripts deposited on authors' or institutional websites are also welcome. All other prior publication is forbidden.

During submission, authors should (1) note use of the preprint repository in the cover letter, (2) state what adjustments and/or updates the draft has undergone between deposition and submission and (3) cite the preprint, including the DOI, as a reference in the manuscript.

After submission to the journal, and until a final decision has been made, authors are discouraged from depositing versions of their manuscript as preprints. Upon publication authors should add a link from the preprint to the published article. Twelve months after publication, authors can update the preprint with the accepted manuscript.

#### **Revision Procedure**

- Should the editors decide that your article requires a revision, you will need to make the changes via a word-processing
  program and resubmit it electronically.
- The best way to make revisions to your manuscript is by enabling the Track Changes mode in Microsoft Word, which will
  automatically highlight and mark up revised text. Please submit both a marked up copy and a clean copy of your revised
  manuscript to the submission system.

## **Peer Review Policy**

All submissions (original articles, reviews, short communications, etc.) that are submitted to the journal are processed through an online submission system and undergo rigorous double-anonymized peer review.

Editors first evaluate manuscripts for alignment with the journal's scope, scientific quality, originality, and general interest to the readership. Manuscripts which are out of journal's scope and lacks novelty or significance would be rejected without external review.

Manuscripts passing initial screening enter a double-anonymized peer review: both authors and reviewers remain anonymous to ensure impartiality. Editors select at least two independent referees with expertise relevant to the manuscript's topic. Editors consolidate reviewers' reports and make the final decision (accept, revise, or reject). Authors receive anonymized reviewer comments to guide revisions. Revised manuscripts are re-evaluated by editors and may be sent back to original reviewers for further assessment.

Editorial board member may be involved in the peer review process. When the editorial board member submits a manuscript, this manuscript is assigned to an independent editor with no personal or professional ties to the author.

#### PRODUCTION PROCEDURE

## **Page Proofs**

Page proofs will be sent to you via email. The proofs will be in a PDF file format, which should be opened using Acrobat Reader software. You will receive further instructions with your proofs. Take this opportunity to check the typeset text for typographic and related errors. Elective alterations are difficult to accommodate owing to the associated time and expense of introducing them. Therefore, please be sure that when you submit your manuscript, it is accurate, complete, and final. The corresponding author will be given an opportunity to proofread the gallery of an accepted manuscript. Major changes are not permitted at this time.

#### **POLICY STATEMENTS**

### Statement on Liability

The legislation on product liability makes increased demands on the duty of care to be exercised by authors of scientific research and medical publications. This applies in particular to papers and publications containing therapeutic directions or instructions and doses or dosage schedules. We therefore request you to examine with particular care, also in your own interest, the factual correctness of the contents of your manuscript once it has been copyedited and returned to you in the form of galley proofs. The responsibility for the correctness of data and statements made in the manuscript rests entirely with the author.

## **Definition of Authorship**

Each author should have made the following contributions towards the completion of the manuscript:

- 1. Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data
- 2. Drafting the article or revising it critically for important intellectual content
- 3. Final approval of the version to be published

## **Copyright Statement**

Submitted manuscripts must represent original research not previously published nor being considered for publication elsewhere. The editors and Thieme combat plagiarism, double publication, and scientific misconduct with the software <a href="CrossCheck">CrossCheck</a> powered by <a href="ITHENTICATE">ITHENTICATE</a>. Your manuscript may be subject to an investigation and retraction if plagiarism is suspected.

If you plan to reproduce text, tables, or figures from a published source, you must first obtain written permission from the copyright holder (usually the publisher). This is required even if the material is from your own published work. For material never before published and given to you by another person, you must obtain permission from that person. Serious delays to publication can be incurred if permissions are not obtained.

As the author, it is your responsibility to obtain all permissions, pay any permission fees, furnish copies of permissions to Thieme with your manuscript, and include a credit line at the end of the figure caption, beneath the table, or in a text footnote.

All papers in *Pharmaceutical Fronts* are published open access and are available online immediately upon publication without registration. Thieme publishes the papers under the terms of the <u>Creative Commons Attribution (CC BY) 4.0</u> license, which permits any user to read, download, copy, distribute, and use the content for any lawful purpose.

## **Clinical Trials**

The Journal supports trial registration. All trials reported must be registered at an official registry recognized by the International Committee of Medical Journal Editors, such as ClinicalTrials.gov ( www.clinicaltrials.gov) or any of the primary registries on the World Health Organization's International Clinical Trial Registry Platform (www.who.int/ictrp).

#### **Ethics**

The journal is very concerned about ethical standards. Please provide proof that the terms of the latest version of the "World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects" have been

adhered to or provide approval of your local ethics committee. The same applies to animals. Please provide proof that experiments involving animals were carried out in compliance with the "Guide for the Care and Use of Laboratory animals" published by the National Academy of Sciences or else provide approval of your local ethics committee.

## **Patient Permission Policy and Thieme GDPR Policy**

You must obtain a signed patient permission form for every patient whose recognizable photograph will be used. If you do not supply this, the identity of the patient must be obscured before the image is published; this could interfere with the instructive value of the photograph.

The personal rights of people who are recognizable on images must be protected. Please provide a written consent form for publication signed by every recognizable person. For persons under 18 years of age / persons supervised, please provide the signature of both parents / the legal guardian / supervisor. A suitable declaration of consent form can be obtained in our authors' lounge. Patient permission forms are available at <a href="https://www.thieme.com/journal-authors">www.thieme.com/journal-authors</a>

We cannot accept or store illustrations in which personal data of third parties are included. Please submit images in completely anonymous form, free of personal data only! Such data may not only be directly visible in the image (e.g., a patient name or a date of birth in an X-ray image); they can also be included in the metadata of the image, which is accessible with the appropriate software. They may also be obscured by a cropping feature (such as PowerPoint or Word), but can be made visible underneath. If you have questions about data protection regulations, please contact us before submitting your manuscript.

## **EDITORIAL CONTACTS**

Please contact the Editors or Thieme Publishers with any questions.

## **Editor in Chief**

Fen-Er Chen, PhD Academician of China Engineering Academy, Professor Department of Chemistry Fudan University 220 Handan Rd. Yangpu District, Shanghai, China

Email: rfchen@fudan.edu.cn

# **Editorial Office**

Lili Zhang 1320 Beijing Xi Lu, JingAn District, Shanghai 200040, P.R. China

Tel: +86 21 6279 3151

Email: zhangll ea pharm@126.com

Lingling Liu 1320 Beijing Xi Lu, JingAn District, Shanghai 200040, P.R. China

Tel: +86 21 6279 3151 Email: cjph\_yygy@163.com

# Thieme Publishers - Acquisitions Publisher

Yingxiao Cai Thieme Publishers

Rm 19-133, Donghuang Building, 16 South Guangshun Street, ChaoYang District,

Beijing 100022 P.R. China Tel: +86 10 9595 0626

Email: Yingxiao.Cai@thieme.com

# Thieme Publishers – Production Editor

Bhanu Priya Budhraja Thieme Medical & Scientific Publishers Pvt. Ltd. A-12, Second Floor, Sector -2, NOIDA -201301, Uttar Pradesh, India

T: +91-0120-4556620 F: +91-0120-4556649 Email: bhanupriya.budhraja@thieme.in